ep top consensu ep beat
better revenu profit factor line ad
ep move reflect beat off-set
weaker segment experi tp stand
revenu profit ahead revenu growth vs estimate
driven stronger core distribut experi partial off-set
suspens product pharmedium facil rose healthi
albeit still estimate repres profit key
compon posit thesi gross margin bp bp
ahead plan oper expens bp bp higher
plan ebit margin deterior bp slightli ahead
view key focu area oper profit distribut came well
plan gener million cash fund
million share repurchas quarter
pre-cal view reiter outperform view ep upsid
stronger distribut perform encourag maintain guid
suggest temper expect compani ramp back
pharmedium busi offici reopen two week ago well
lighter experi chatter washington continu
weigh suppli chain servic name view remain best
posit amongst distributor given increas focu non-tradit
busi focu call also lash perform generic/
brand price environ hh commentari overal see revenu
profit driver wba matur pharmaci network relationship
onboard upcom acceler esrx relationship contribut
diversifi non-cor unit risk demand shift miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
similar
low end
sell side still see
competit rel stabl
continu evalu much
valu expectclearli
month juli run rate
less would
competit less price
competit less price
buysid in-lin expect
sell-sid see
market environ competit
stabl
slightli msd full-year
mid-single-digit high-singl digit
compani mention price
